STOCK TITAN

Tourmaline Bio to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotech company, has announced its participation in two upcoming investor conferences. CEO Sandeep Kulkarni is scheduled to present at:

  • H.C. Wainwright 26th Annual Global Investor Conference in New York on September 9, 2024 at 12:00 pm ET
  • Cantor Global Healthcare Conference in New York on September 17, 2024 at 3:40 pm ET

Both presentations will be available via live webcast on the company's website under the 'Events and Presentations' section. Replays will be archived on the site after each event. Tourmaline Bio focuses on developing transformative medicines for immune and inflammatory diseases.

Tourmaline Bio (NASDAQ: TRML), un'azienda biotecnologica clinica in fase avanzata, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'amministratore delegato Sandeep Kulkarni è programmato per presentare:

  • H.C. Wainwright 26° Annual Global Investor Conference a New York il 9 settembre 2024 alle 12:00 ET
  • Cantor Global Healthcare Conference a New York il 17 settembre 2024 alle 15:40 ET

Entrambe le presentazioni saranno disponibili tramite webcast in diretta sul sito web dell'azienda nella sezione 'Eventi e Presentazioni'. Le registrazioni saranno archiviate sul sito dopo ogni evento. Tourmaline Bio si concentra sullo sviluppo di medicinali trasformativi per malattie immunitarie e infiammatorie.

Tourmaline Bio (NASDAQ: TRML), una empresa biotecnológica clínica en etapa avanzada, ha anunciado su participación en dos próximas conferencias para inversores. El CEO Sandeep Kulkarni está programado para presentar en:

  • H.C. Wainwright 26ª Conferencia Global Anual de Inversores en Nueva York el 9 de septiembre de 2024 a las 12:00 pm ET
  • Conferencia Global de Salud de Cantor en Nueva York el 17 de septiembre de 2024 a las 3:40 pm ET

Ambas presentaciones estarán disponibles a través de webcast en vivo en el sitio web de la empresa en la sección 'Eventos y Presentaciones'. Las repeticiones se archivarán en el sitio después de cada evento. Tourmaline Bio se centra en el desarrollo de medicamentos transformadores para enfermedades inmunitarias e inflamatorias.

투말린 바이오 (NASDAQ: TRML)은 후기 단계의 임상 생명공학 회사로서 두 가지 예정된 투자자 회의에 참가한다고 발표했습니다. CEO 산딥 쿨카르니는 다음과 같이 발표할 예정입니다:

  • 뉴욕에서 열리는 H.C. 웨인라이트 제26회 글로벌 투자자 회의에서 2024년 9월 9일 오후 12시 ET
  • 뉴욕에서 열리는 칸토 글로벌 헬스케어 회의에서 2024년 9월 17일 오후 3시 40분 ET

두 발표 모두 회사 웹사이트의 '이벤트 및 발표' 섹션에서 실시간 웹캐스트를 통해 제공될 것입니다. 각 행사 후에는 웹사이트에 다시 보기 자료가 보관됩니다. 투말린 바이오는 면역 및 염증 질환을 위한 혁신적인 의약품 개발에 집중하고 있습니다.

Tourmaline Bio (NASDAQ: TRML), une entreprise de biotechnologie clinique en phase avancée, a annoncé sa participation à deux prochaines conférences pour investisseurs. Le PDG Sandeep Kulkarni est programmé pour présenter :

  • La 26e Conférence Annuelle des Investisseurs Mondiaux H.C. Wainwright à New York le 9 septembre 2024 à 12h00 ET
  • La Conférence Mondiale sur la Santé de Cantor à New York le 17 septembre 2024 à 15h40 ET

Les deux présentations seront disponibles par le biais d'un webinaire en direct sur le site web de l'entreprise dans la section 'Événements et Présentations'. Les rediffusions seront archivées sur le site après chaque événement. Tourmaline Bio se concentre sur le développement de médicaments transformateurs pour les maladies immunitaires et inflammatoires.

Tourmaline Bio (NASDAQ: TRML), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. CEO Sandeep Kulkarni wird präsentieren:

  • H.C. Wainwright 26. jährliche globale Investorenkonferenz in New York am 9. September 2024 um 12:00 Uhr ET
  • Cantor Global Healthcare Conference in New York am 17. September 2024 um 15:40 Uhr ET

Beide Präsentationen werden über den Live-Webcast auf der Website des Unternehmens im Bereich 'Veranstaltungen und Präsentationen' verfügbar sein. Nach jeder Veranstaltung werden Aufzeichnungen auf der Website archiviert. Tourmaline Bio konzentriert sich auf die Entwicklung von transformierenden Arzneimitteln für immunologische und entzündliche Erkrankungen.

Positive
  • None.
Negative
  • None.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conferences:

H.C. Wainwright 26th Annual Global Investor Conference, New York
Fireside Chat
Monday, September 9, 2024 at 12:00 pm ET

Cantor Global Healthcare Conference, New York
Fireside Chat
Tuesday, September 17, 2024 at 3:40 pm ET

A live webcast of both presentations will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com. A replay of the webcasts will be archived on the Tourmaline Bio website following each event.

About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in TED and ASCVD as its first two indications, with additional diseases under consideration.

Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com


FAQ

When is Tourmaline Bio (TRML) presenting at the H.C. Wainwright Global Investor Conference?

Tourmaline Bio (TRML) is presenting at the H.C. Wainwright 26th Annual Global Investor Conference on Monday, September 9, 2024 at 12:00 pm ET in New York.

What time is Tourmaline Bio's (TRML) presentation at the Cantor Global Healthcare Conference?

Tourmaline Bio (TRML) is scheduled to present at the Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 3:40 pm ET in New York.

How can investors access Tourmaline Bio's (TRML) investor conference presentations?

Investors can access live webcasts of Tourmaline Bio's (TRML) presentations under the 'Events and Presentations' section in the News & Investors area of the company's website at ir.tourmalinebio.com.

Will replays of Tourmaline Bio's (TRML) investor conference presentations be available?

Yes, replays of Tourmaline Bio's (TRML) investor conference presentations will be archived on the company's website following each event.

Tourmaline Bio, Inc.

NASDAQ:TRML

TRML Rankings

TRML Latest News

TRML Stock Data

691.16M
25.64M
22.62%
84.28%
8.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK